69 results
6-K
EX-99
BLRX
Bioline Rx Ltd
17 May 24
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
5:07pm
; whether BioLineRx’s collaboration partners will be able to execute on collaboration goals in a timely manner; whether the clinical trial results
6-K
EX-99
BLRX
Bioline Rx Ltd
6 May 24
Current report (foreign)
7:14am
; whether BioLineRx's collaboration partners will be able to execute on collaboration goals in a timely manner; whether the clinical trial results
6-K
EX-99.1
BLRX
Bioline Rx Ltd
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
to execute on collaboration goals in a timely manner; whether the clinical trial results for APHEXDA will be predictive of real-world results; BioLineRx's
6-K
EX-99
BLRX
Bioline Rx Ltd
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
partners will be able to execute on collaboration goals in a timely manner; whether the clinical trial results for APHEXDA will be predictive of real
6-K
EX-99.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
BioLineRx’s collaboration partners will be able to execute on collaboration goals in a timely manner; whether the clinical trial results for APHEXDA
20-F/A
q3jk9d1w3795w
26 Mar 24
Annual report (foreign) (amended)
4:57pm
20-F/A
EX-2.1
f93 9ta9l
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
EX-99
0cql0guwunhtk qhc8u8
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
z9w48l
4 Mar 24
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
7:47am
6-K
EX-99
fjx7n8ea c9fuj2trwnl
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
6-K
EX-1
b2mneg dwdj
16 Feb 24
Current report (foreign)
7:07am
6-K
EX-99
rl507283yr2wd9k2
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am
6-K
EX-99
jruroc
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
f7xtojlniri2wk25q
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
6oz4u8
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
3796fr
15 Sep 22
Current report (foreign)
8:39am
6-K
EX-99
2is4n6ie h7d
27 May 22
2022 Annual General Meeting of Shareholders
4:30pm